News & articles
Avidity Biosciences Investor & Analyst Event: FORTITUDE™ Topline Data and Regulatory Updates for del-brax in FSHD
Avidity announced topline data in the del-brax program demonstrating consistent improvement across multiple functional measures compared to placebo. Data will be presented at the 32nd Annual FSHD Society International Research Congress (IRC) in Amsterdam. More...
FDA clears Phase 1 clinical trial of DYNE-302 for FSHD
FDA clearance allows Dyne Therapeutics to begin the first Phase 1 clinical trial of DYNE-302, an investigational therapy targeting DUX4 in FSHD.
Chicago highlights: progress, partnerships, and momentum for FSHD
16 July 2026 The global FSHD community came together in Chicago for the FSHD International Research Congress (IRC) 2026, FSHD Connect, and the Project Mercury Global Task Force meeting – a week filled with scientific progress, collaboration, and renewed commitment to...
Roche and FSHD Europe meet to discuss emugrobart Phase 2 study results
15 July 2026. On 9 July 2026, members of the Roche Patient Partnership Team and European representatives of the FSHD Patient Advocacy Group met to discuss the results of the Phase 2 MANOEUVRE study of the investigational therapy emugrobart for FSHD. Roche has worked...
Encouraging results from the Novartis Phase I/II FORTITUDE clinical trial
Novartis has announced encouraging results from the Phase I/II FORTITUDE clinical trial of delpacibart braxlosiran (del-brax), an investigational treatment for FSHD. The study met its primary biomarker endpoint, marking an important step forward in the development of potential disease-modifying treatments for FSHD.
Encouraging early results from the EPI-321 clinical trial for FSHD
Encouraging early results from the EPI-321 clinical trial for FSHD
Recent news from the FSHD research pipeline has brought cautious optimism to our FSHD community. Epicrispr Biotechnologies has announced encouraging early findings from its ongoing Phase 1/2 clinical trial of EPI-321, an investigational therapy designed to target the root cause of FSHD.
Italy’s FSHD community gathers in Rome — because no one gets left behind
Italy’s FSHD community gathers in Rome on World FSHD Day
On 20 June 2026, FSHD Italia APS will host the XII National FSHD Conference in Rome — on World FSHD Day itself — bringing together patients, caregivers, clinicians and researchers for a full day of science, advocacy and community. The event takes place at UNA Hotels Decò (Sala Campidoglio), is free of charge and available in live streaming, with prior registration.
The conference is organised in collaboration with UILDM and the FSHD Group of AIM (Italian Association of Myology).
Join Us!
We aim to be open and transparent in our approach and be respectful of cultural differences and the priorities of individual member organisations.





